In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf

Linda Hammerich, Adam Binder, Joshua D. Brody

Research output: Contribution to journalReview article

44 Citations (Scopus)

Abstract

As cancer immunotherapy continues to benefit from novel approaches which cut immune 'brake pedals' (e.g. anti-PD1 and anti-CTLA4 antibodies) and push immune cell gas pedals (e.g. IL2, and IFNα) there will be increasing need to develop immune 'steering wheels' such as vaccines to guide the immune system specifically toward tumor associated antigens. Two primary hurdles in cancer vaccines have been: identification of universal antigens to be used in 'off-the-shelf' vaccines for common cancers, and 2) logistical hurdles of ex vivo production of individualized whole tumor cell vaccines. Here we summarize approaches using '. in situ vaccination' in which intratumoral administration of off-the-shelf immunomodulators have been developed to specifically induce (or amplify) T cell responses to each patient's individual tumor. Clinical studies have confirmed the induction of systemic immune and clinical responses to such approaches and preclinical models have suggested ways to further potentiate the translation of in situ vaccine trials for our patients.

Original languageEnglish (US)
Pages (from-to)1966-1981
Number of pages16
JournalMolecular Oncology
Volume9
Issue number10
DOIs
StatePublished - Dec 1 2015
Externally publishedYes

Fingerprint

Cancer Vaccines
Immunotherapy
Vaccination
Foot
Vaccines
Neoplasms
Immunologic Factors
Neoplasm Antigens
Interleukin-2
Anti-Idiotypic Antibodies
Immune System
Gases
T-Lymphocytes
Antigens

Keywords

  • Cancer immunotherapy
  • Checkpoint blockade
  • Dendritic cells
  • In situ vaccination
  • Oncolytic viruses
  • Toll like receptors

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Cancer Research

Cite this

In situ vaccination : Cancer immunotherapy both personalized and off-the-shelf. / Hammerich, Linda; Binder, Adam; Brody, Joshua D.

In: Molecular Oncology, Vol. 9, No. 10, 01.12.2015, p. 1966-1981.

Research output: Contribution to journalReview article

Hammerich, Linda ; Binder, Adam ; Brody, Joshua D. / In situ vaccination : Cancer immunotherapy both personalized and off-the-shelf. In: Molecular Oncology. 2015 ; Vol. 9, No. 10. pp. 1966-1981.
@article{03224ac930ad42569aa46389d75f3975,
title = "In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf",
abstract = "As cancer immunotherapy continues to benefit from novel approaches which cut immune 'brake pedals' (e.g. anti-PD1 and anti-CTLA4 antibodies) and push immune cell gas pedals (e.g. IL2, and IFNα) there will be increasing need to develop immune 'steering wheels' such as vaccines to guide the immune system specifically toward tumor associated antigens. Two primary hurdles in cancer vaccines have been: identification of universal antigens to be used in 'off-the-shelf' vaccines for common cancers, and 2) logistical hurdles of ex vivo production of individualized whole tumor cell vaccines. Here we summarize approaches using '. in situ vaccination' in which intratumoral administration of off-the-shelf immunomodulators have been developed to specifically induce (or amplify) T cell responses to each patient's individual tumor. Clinical studies have confirmed the induction of systemic immune and clinical responses to such approaches and preclinical models have suggested ways to further potentiate the translation of in situ vaccine trials for our patients.",
keywords = "Cancer immunotherapy, Checkpoint blockade, Dendritic cells, In situ vaccination, Oncolytic viruses, Toll like receptors",
author = "Linda Hammerich and Adam Binder and Brody, {Joshua D.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.molonc.2015.10.016",
language = "English (US)",
volume = "9",
pages = "1966--1981",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "10",

}

TY - JOUR

T1 - In situ vaccination

T2 - Cancer immunotherapy both personalized and off-the-shelf

AU - Hammerich, Linda

AU - Binder, Adam

AU - Brody, Joshua D.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - As cancer immunotherapy continues to benefit from novel approaches which cut immune 'brake pedals' (e.g. anti-PD1 and anti-CTLA4 antibodies) and push immune cell gas pedals (e.g. IL2, and IFNα) there will be increasing need to develop immune 'steering wheels' such as vaccines to guide the immune system specifically toward tumor associated antigens. Two primary hurdles in cancer vaccines have been: identification of universal antigens to be used in 'off-the-shelf' vaccines for common cancers, and 2) logistical hurdles of ex vivo production of individualized whole tumor cell vaccines. Here we summarize approaches using '. in situ vaccination' in which intratumoral administration of off-the-shelf immunomodulators have been developed to specifically induce (or amplify) T cell responses to each patient's individual tumor. Clinical studies have confirmed the induction of systemic immune and clinical responses to such approaches and preclinical models have suggested ways to further potentiate the translation of in situ vaccine trials for our patients.

AB - As cancer immunotherapy continues to benefit from novel approaches which cut immune 'brake pedals' (e.g. anti-PD1 and anti-CTLA4 antibodies) and push immune cell gas pedals (e.g. IL2, and IFNα) there will be increasing need to develop immune 'steering wheels' such as vaccines to guide the immune system specifically toward tumor associated antigens. Two primary hurdles in cancer vaccines have been: identification of universal antigens to be used in 'off-the-shelf' vaccines for common cancers, and 2) logistical hurdles of ex vivo production of individualized whole tumor cell vaccines. Here we summarize approaches using '. in situ vaccination' in which intratumoral administration of off-the-shelf immunomodulators have been developed to specifically induce (or amplify) T cell responses to each patient's individual tumor. Clinical studies have confirmed the induction of systemic immune and clinical responses to such approaches and preclinical models have suggested ways to further potentiate the translation of in situ vaccine trials for our patients.

KW - Cancer immunotherapy

KW - Checkpoint blockade

KW - Dendritic cells

KW - In situ vaccination

KW - Oncolytic viruses

KW - Toll like receptors

UR - http://www.scopus.com/inward/record.url?scp=84951802073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951802073&partnerID=8YFLogxK

U2 - 10.1016/j.molonc.2015.10.016

DO - 10.1016/j.molonc.2015.10.016

M3 - Review article

C2 - 26632446

AN - SCOPUS:84951802073

VL - 9

SP - 1966

EP - 1981

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 10

ER -